Olympus to acquire BioProtect for US$270M to expand urology portfolio

JAPAN—Olympus has agreed to acquire Israel-based medical technology company BioProtect in a UIS$270 million transaction, strengthening its portfolio in prostate cancer care and expanding its presence in adjacent urology and endoscopy markets.

The deal gives Olympus access to BioProtect’s commercially available implant system designed to protect healthy tissue during radiation therapy.

The acquisition aligns with the Japanese company’s strategy to broaden its surgical and interventional solutions portfolio while accelerating innovation in minimally invasive treatment tools across global healthcare markets.

Balloon Spacer technology and clinical adoption

BioProtect’s lead product, Balloon Spacer, is an implantable system that creates a temporary physical barrier between the prostate and surrounding organs, such as the rectum, during radiation therapy.

The device reduces radiation exposure to healthy tissues and improves treatment precision during oncology procedures.

Once its role is complete, the spacer naturally biodegrades within the body, removing the need for surgical removal.

Since its commercial launch in 2023, clinicians have used the system in more than 11,000 procedures across the United States and Europe, reflecting growing clinical adoption.

Deal structure and integration timeline

Olympus said certain portions of the transaction value will be held in escrow for a defined period, depending on the continued performance of BioProtect’s operations.

The company expects to complete the acquisition by the second quarter of fiscal year 2026.

Management noted that integrating BioProtect’s technology with Olympus’ global commercial network will help expand access to advanced prostate cancer care solutions and strengthen engagement with healthcare professionals in urology and oncology fields.

Corporate strategy and workforce restructuring

Olympus continues to pursue an innovation-driven growth strategy aimed at reinforcing its position in endoscopy and related therapeutic areas, including gastrointestinal and urological care.

At the same time, the company has been restructuring operations following challenges in its endoscopy business.

In November 2025, Olympus announced plans to reduce its workforce by around 2,000 employees as part of efforts to simplify operations and improve managerial accountability across divisions.

The restructuring seeks to streamline decision-making and enhance efficiency across global operations.

Regulatory pressure and product quality focus

Olympus has also faced regulatory scrutiny in recent years, including a Class I recall issued by the US Food and Drug Administration in December 2023 after reports of patient deaths and injuries linked to endobronchial burns from certain bronchoscopes.

In 2024, additional safety concerns emerged when another endoscope component was associated with a patient death and multiple injuries.

These developments have increased the company’s focus on product quality, regulatory compliance, and portfolio modernization as it works to restore confidence in its endoscopy technologies.